An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential

Clinical and Experimental Allergy

Volumn 42, Issue 12, 2012, Pages 1801-1812

  Starkl, P ^a   Felix, F ^a   Krishnamurthy, D ^a   Stremnitzer, C ^a   Roth Walter, F ^a,b   Prickett, S R ^c,d   Voskamp, A L ^c,d   Willensdorfer, A ^a,b   Szalai, K ^b   Weichselbaumer, M ^a   O'Hehir, R E ^c,d   Jensen Jarolim, E ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Alkylation; Anaphylaxis; Food allergy; Human T cells; Hypoallergen; Immunotherapy; Mouse model; Splenocytes; Unfolded peanut allergen Ara h 2

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; PEANUT ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALKYLATION; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASOPHIL DEGRANULATION; CHILD; CIRCULAR DICHROISM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PEANUT ALLERGY; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCTION; SCHOOL CHILD; SENSITIZATION; SPLEEN CELL; T LYMPHOCYTE; WESTERN BLOTTING;

2S ALBUMINS, PLANT; ADOLESCENT; ALKYLATION; ANAPHYLAXIS; ANIMALS; ANTIGENS, PLANT; CHILD; CHILD, PRESCHOOL; CIRCULAR DICHROISM; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MICE; PEANUT HYPERSENSITIVITY; PROTEIN UNFOLDING; SPECTRUM ANALYSIS; TREATMENT OUTCOME;

EID: 84870217012     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12031     Document Type: Article

References (42)

1. Nowak-Wegrzyn A, Sampson HA. Future therapies for food allergies. J Allergy Clin Immunol 2011; 127:558-73.
2. Leung DY, Sampson HA, Yunginger JW et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-93.
3. Sampson HA, Leung DY, Burks AW et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309-10.
4. Hol J, van Leer EH, Elink Schuurman BE et al. The acquisition of tolerance toward cow's milk through probiotic supplementation: a randomized, controlled trial. J Allergy Clin Immunol 2008; 121:1448-54.
5. Wang J, Patil SP, Yang N et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 2010; 105:75-84.
6. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy 2006; 36:273-82.
7. Cady CT, Powell MS, Harbeck RJ et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett 2010; 130:57-65.
8. Uermosi C, Beerli RR, Bauer M et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010; 126:375-83.
9. Schmitz N, Dietmeier K, Bauer M et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206:1941-55.
10. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127:18-27.
11. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205:2887-98.
12. Rolland JM, Gardner LM, O'Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009; 121:273-84.
13. Chen KW, Fuchs G, Sonneck K et al. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol Immunol 2008; 45:2486-98.
14. Kahlert H, Suck R, Weber B et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008; 145:193-206.
15. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010; 125:1322-6.
16. Ben-Shoshan M, Kagan RS, Alizadehfar R et al. Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal. J Allergy Clin Immunol 2009; 123:783-8.
17. Mullins RJ, Dear KB, Tang ML. Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007. J Allergy Clin Immunol 2009; 123:689-93.
18. Hourihane JO, Aiken R, Briggs R et al. The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol 2007; 119:1197-202.
19. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99:744-51.
20. Koppelman SJ, Wensing M, Ertmann M, Knulst AC, Knol EF. Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil-histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen. Clin Exp Allergy 2004; 34:583-90.
21. McDermott RA, Porterfield HS, El MR et al. Contribution of Ara h 2 to peanut-specific, immunoglobulin E-mediated, cell activation. Clin Exp Allergy 2007; 37:752-63.
22. Flinterman AE, van Hoffen E, den Hartog Jager CF et al. Children with peanut allergy recognize predominantly Ara h2 and Ara h6, which remains stable over time. Clin Exp Allergy 2007; 37:1221-8.
23. Starkl P, Krishnamurthy D, Szalai K et al. Heating affects structure, Enterocyte adsorption and signalling, as well as immunogenicity of the Peanut allergen Ara h 2. Open Allergy J 2011; 4:24-34.
24. Vissers YM, Blanc F, Skov PS et al. Effect of heating and glycation on the allergenicity of 2S albumins (Ara h 2/6) from peanut. PLoS ONE 2011; 6:e23998.
25. Hale JE, Butler JP, Gelfanova V, You JS, Knierman MD. A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal Biochem 2004; 333:174-81.
26. Toda M, Reese G, Gadermaier G et al. Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J Allergy Clin Immunol 2011; 128:1022-30, e1-7.
27. Albrecht M, Kuhne Y, Ballmer-Weber BK et al. Relevance of IgE binding to short peptides for the allergenic activity of food allergens. J Allergy Clin Immunol 2009; 124:328-36.
28. Swoboda I, Bugajska-Schretter A, Verdino P et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J Immunol 2002; 168:4576-84.
29. Scudiero DA, Shoemaker RH, Paull KD et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48:4827-33.
30. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39:3402-8.
31. Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE. Ara h 2 peptides containing dominant CD4 + T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011; 127:608-15.
32. Mueller GA, Gosavi RA, Pomes A et al. Ara h 2: crystal structure and IgE binding distinguish two subpopulations of peanut allergic patients by epitope diversity. Allergy 2011; 66:878-85.
33. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12.
34. Cooke SK, Sampson HA. Allergenic properties of ovomucoid in man. J Immunol 1997; 159:2026-32.
35. Lehmann K, Schweimer K, Reese G et al. Structure and stability of 2S albumin-type peanut allergens: implications for the severity of peanut allergic reactions. Biochem J 2006; 395:463-72.
36. Christensen LH, Holm J, Lund G, Riise E, Lund K. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol 2008; 122:298-304.
37. Magone MT, Chan CC, Beck L, Whitcup SM, Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000; 30:1841-50.
38. Horner AA, Nguyen MD, Ronaghy A, Cinman N, Verbeek S, Raz E. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 2000; 106:349-56.
39. Porterfield HS, Murray KS, Schlichting DG et al. Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. Clin Exp Allergy 2009; 39:1099-108.
40. Blanc F, Adel-Patient K, Drumare MF, Paty E, Wal JM, Bernard H. Capacity of purified peanut allergens to induce degranulation in a functional in vitro assay: Ara h 2 and Ara h 6 are the most efficient elicitors. Clin Exp Allergy 2009; 39:1277-85.
41. Chen X, Zhuang Y, Wang Q et al. Analysis of the effector activity of Ara h 2 and Ara h 6 by selective depletion from a crude peanut extract. J Immunol Methods 2011; 372:65-70.
42. Mueller UR. Insect sting allergy: clinical picture, diagnosis and treatment. New York: Gustav Fischer Verlag, 1990.